Loading...
01/10 16:05
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary presents a mixed picture. Positive aspects include potential revenue synergies from the FitLife-Irwin merger and the likelihood of inclusion in the Russell 2000 Index. However, the lack of forward-looking guidance and challenges with Dr. Tobias brand balance these positives. The Q&A section reinforces this neutral stance with uncertainties regarding Irwin's revenue growth and the integration process. Overall, the absence of clear guidance and the focus on addressing brand challenges suggest a cautious market reaction, resulting in a neutral stock price prediction.
Total Revenue Declined 5% year-over-year to $16.1 million. The decline is attributed to overall market conditions.
Online Sales $10.4 million or 65% of total revenue. No year-over-year change mentioned.
Gross Profit Declined 9%. Gross margin declined from 44.8% to 42.8% year-over-year. The decline is due to increased costs and market conditions.
Net Income $1.7 million compared to $2.6 million in the previous year, a decline attributed to elevated merger and acquisition-related expenses.
Basic Earnings Per Share Declined from $0.29 to $0.19 year-over-year.
Diluted Earnings Per Share Declined from $0.27 to $0.18 year-over-year.
Adjusted EBITDA $3.3 million, a 13% decrease year-over-year, bringing the trailing 12 months to $13.4 million.
Net Debt $4.3 million, equivalent to approximately 0.3x the company's adjusted EBITDA.
Legacy FitLife Revenue $7.3 million, a 7% increase year-over-year. Wholesale revenue increased 1%, and online revenue increased 17%.
Legacy FitLife Gross Margin Increased to 43.8% compared to 44.2% in the previous year.
MRC Revenue $6.3 million, down 16% year-over-year. Decline attributed to tariffs and product mix issues.
MRC Gross Margin Declined to 46.5% from 48.2% year-over-year. Tariffs and product mix were the primary reasons for the decline.
MusclePharm Revenue Declined 4% year-over-year. Wholesale revenue declined 6%, and online revenue declined 3%.
MusclePharm Gross Margin Declined from 36.6% to 30.8% year-over-year. Decline attributed to targeted investments in advertising and promotion.
MusclePharm Pro Series: Launched in mid-March 2025 as a collection of premium sports nutrition products. Initially piloted in high-volume Vitamin Shoppe stores and later expanded to online and international wholesale partners.
Irwin Naturals Acquisition: FitLife completed the acquisition of Irwin Naturals and its affiliates on August 8, 2025. Irwin's nutritional supplement business generated approximately $60 million in revenue for the trailing 12 months as of June 30, 2025, with a gross margin of 35%. The acquisition is expected to contribute to combined revenue exceeding $120 million and adjusted EBITDA of $20-$25 million for the first full year of operations.
Revenue Decline: Total revenue declined 5% year-over-year to $16.1 million in Q2 2025. Online sales accounted for 65% of total revenue.
Legacy FitLife Performance: Legacy FitLife revenue increased 7% year-over-year to $7.3 million, driven by a 17% increase in online sales and a 1% increase in wholesale revenue.
MRC Performance: Revenue declined 16% year-over-year to $6.3 million, with gross margin dropping to 46.5% due to tariffs and product mix issues.
MusclePharm Performance: Revenue declined 4% year-over-year, with gross margin falling from 36.6% to 30.8%. Targeted advertising and promotional investments are ongoing to drive growth.
Irwin Naturals Bankruptcy and Strategic Shift: Irwin Naturals faced bankruptcy due to an unsuccessful expansion into ketamine clinics. FitLife acquired the brand, refocusing on its core nutritional supplement business and aiming for operational improvements.
Revenue Decline: Total revenue declined 5% year-over-year to $16.1 million, with gross profit and gross margin also decreasing. This indicates potential challenges in maintaining sales growth and profitability.
M&A-Related Expenses: Elevated merger and acquisition-related expenses associated with the acquisition of Irwin Naturals negatively impacted net income, which declined from $2.6 million to $1.7 million year-over-year.
MRC Brand Challenges: MRC revenue declined 16% year-over-year, with gross margin dropping due to tariffs and unfavorable product mix. Contribution also decreased, indicating operational inefficiencies.
Tariffs Impact: A 25% tariff on skincare brands under MRC significantly reduced gross margins, cutting profitability for these products by approximately half.
MusclePharm Revenue Decline: MusclePharm revenue declined 4%, with gross margin dropping from 36.6% to 30.8%. Targeted advertising and promotional investments have yet to yield consistent growth.
Dr. Tobias Brand Traffic Issues: The Dr. Tobias brand is experiencing reduced session counts on Amazon, leading to lower traffic despite stable conversion rates. This poses a challenge in driving online sales growth.
Irwin Naturals Bankruptcy History: Irwin Naturals faced bankruptcy due to failed expansion into ketamine clinics and loss of major customers like Costco U.S., raising concerns about its operational stability and integration risks.
Post-Acquisition Uncertainties: Uncertainties related to the integration of Irwin Naturals and achieving projected revenue and EBITDA targets could impact overall business performance.
Revenue and Adjusted EBITDA Projections: For the first full year of operations, the combined FitLife and Irwin businesses are expected to generate in excess of $120 million of revenue and adjusted EBITDA of between $20 million to $25 million.
Irwin Naturals Gross Margin Improvement: FitLife expects to improve Irwin Naturals' gross margins over time by increasing the percentage of revenue generated from online sales and focusing on making the supply chain more efficient.
Irwin Naturals SG&A Reduction: Annual SG&A for Irwin Naturals is expected to be approximately $1.5 million lower based on the number of employees rehired by FitLife as part of the transaction, with further cost savings opportunities anticipated.
MusclePharm Revenue Growth Initiatives: The company is making targeted investments in advertising and promotion in both wholesale and online channels to drive revenue growth for the MusclePharm brand. Additional promotional incentives are being offered to certain wholesale partners.
Dr. Tobias Brand Traffic Initiatives: FitLife is focused on increasing session counts for the Dr. Tobias brand through targeted advertising spend, improved SEO, and driving external traffic to Amazon product pages. Year-over-year comparisons are expected to be more favorable later in the year if session counts remain stable.
The selected topic was not discussed during the call.
The earnings call reveals several negative factors: declining margins, increased tax expenses, and unresolved issues with Dr. Tobias on Amazon. Although MusclePharm shows growth, it's primarily from existing customers. Rising protein costs and potential further margin declines are concerning. Despite optimistic guidance for Irwin's online sales, the lack of clarity on subscriber trends and management's avoidance of detailed responses contribute to a negative sentiment. Without a market cap, the negative impact is assumed to be moderate.
The earnings call summary presents a mixed picture. Positive aspects include potential revenue synergies from the FitLife-Irwin merger and the likelihood of inclusion in the Russell 2000 Index. However, the lack of forward-looking guidance and challenges with Dr. Tobias brand balance these positives. The Q&A section reinforces this neutral stance with uncertainties regarding Irwin's revenue growth and the integration process. Overall, the absence of clear guidance and the focus on addressing brand challenges suggest a cautious market reaction, resulting in a neutral stock price prediction.
The earnings call highlights several negative aspects: declining revenue and gross profit, reduced margins, significant M&A expenses, and wholesale revenue decline. The Q&A session lacked clarity on MusclePharm's performance and margins, adding uncertainty. Despite some positive aspects like online sales growth and product launches, the weak guidance, declining margins, and absence of a share buyback program suggest a negative market reaction.
The earnings call summary shows strong financial performance with increased gross margin and contribution, and significant revenue growth. Despite a decline in online revenue, wholesale revenue surged, and adjusted EBITDA rose 39% YoY. The Q&A highlighted optimism in rebranding and new products, though management was vague on some details. The lack of new partnerships or guidance changes, and no severe risks identified, points to a positive sentiment. However, uncertainties in promotional expenses and GNC relations slightly temper the outlook, resulting in a positive stock price prediction.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
